Alys Pharmaceuticals

What Alys Pharmaceuticals does

Alys Pharmaceuticals is a clinical-stage biopharmaceutical company focused exclusively on immuno-dermatology, founded in February 2024 through the strategic merger of six asset-centric Medicxi portfolio companies (Aldena Therapeutics, Graegis Pharmaceuticals, Granular Therapeutics, Klirna Biotech, Nira Biosciences, and Vimela Therapeutics) with a $100 million seed financing from Medicxi. The company is headquartered in Boston, Massachusetts, with European operations in the Geneva/Lausanne area and operates through six wholly-owned subsidiaries that each maintain a distinct technology platform: siRNA-lipid conjugates (Aldena), mast cell-selective bispecific antibodies (Granular), intraneuronal itch targeting (Klirna), photoimmunotherapy (Nira), topical vitiligo therapy (Vimela), and dermatological supportive care for oncology patients (Graegis). Alys currently has two clinical-stage drug candidates: ALY-101, an intradermal injectable JAK1 siRNA-lipid conjugate in Phase 2a for alopecia areata that received FDA Fast Track designation; and ALY-301, a first-in-class cis-targeting bispecific antibody against c-Kit and CD203c in Phase 1/1b for chronic inducible urticaria (cold urticaria), being conducted at Charité Berlin. The broader pipeline comprises more than a dozen active programs targeting atopic dermatitis, vitiligo, psoriasis, chronic urticaria, mastocytosis, and CTCL, with a stated goal of delivering 7-10 clinical proof-of-concept readouts and at least one registrational program within three years of launch.

The company is pre-revenue and will generate future revenue through sales of FDA-approved pharmaceutical products in dermatology. Its near-term go-to-market motion is enterprise-field-sales-style distribution through clinical trial sites and, upon approval, traditional pharmaceutical channels including specialty dermatology clinics, hospitals, and pharmacies. Pricing has not been disclosed and will be determined at launch. Customer segments are defined by indication (patients with atopic dermatitis, vitiligo, alopecia areata, chronic urticaria, mastocytosis, etc.) and prescriber base (dermatologists and clinical investigators). The company is led by co-founder and Acting COO Thibaud Portal (formerly Global Head of Research at Galderma), with Nobel Laureate Craig Mello, John Harris (Mass General Brigham), Brian Kim (Mount Sinai), Lars French (LMU Munich), Eric Deutsch (Gustave Roussy), and Mark Prausnitz (Georgia Tech) as scientific co-founders, and Francesco De Rubertis (Medicxi) as Executive Chairman.

Name

Alys Pharmaceuticals

Legal name

Alys Pharmaceuticals, Inc.

Website

https://alyspharma.com

Company type

Private

Founded year

2024

Operating status

Operating

Headcount range

11–50 employees

Short description

Alys Pharmaceuticals is a clinical-stage biopharmaceutical company developing multi-platform immuno-dermatology treatments, with siRNA and bispecific antibody candidates in Phase 1/2 trials for alopecia areata and chronic urticaria, backed by Medicxi.

Ownership category

akta.pro rank

Product category

Immuno-dermatology Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Dermatology Specialty Pharmaceuticals (HLAIACAL)

akta.pro secondary industry

Immunology & Inflammation Pharmaceuticals (HLAIAAAD)

Keywords

• Immuno-dermatology therapeutics
• SiRNA drug development
• Bispecific antibodies
• Dermatology clinical pipeline
• Biopharmaceutical drug candidates

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical product sales: Pre-revenue clinical stage biotech company developing immuno-dermatology drugs. Revenue will be generated through sales of FDA-approved pharmaceutical products targeting dermatological conditions including atopic dermatitis, vitiligo, alopecia areata, chronic urticaria, psoriasis, and mastocytosis.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

Alys Pharmaceuticals is a clinical-stage biopharmaceutical company developing immuno-dermatology drug candidates targeting inflammatory and autoimmune skin diseases. The pipeline includes ALY-101 (a JAK1 siRNA-lipid conjugate in Phase 2a for Alopecia Areata) and ALY-301 (a first-in-class mast cell-selective c-Kit bispecific antibody in Phase 1/1b for Chronic Urticaria), supported by more than a dozen active preclinical and clinical programs addressing atopic dermatitis, vitiligo, psoriasis, mastocytosis, and dermatological side effects of oncology therapies.

Product overview

Alys Pharmaceuticals is a pure-play immuno-dermatology company structured as a multi-platform pipeline with six operating subsidiaries. The company operates two main clinical-stage drug candidates: ALY-101 (siRNA-lipid conjugate for Alopecia Areata, Phase IIa) and ALY-301 (bispecific antibody for Chronic Urticaria, Phase 1/1b). The portfolio includes platform technologies spanning siRNA therapeutics (Aldena Therapeutics), mast cell-targeted biologics (Granular Therapeutics), photoimmunotherapy (Nira Biosciences), intraneuronal itch targeting (Klirna Biotech), topical vitiligo therapy (Vimela Therapeutics), and dermatological supportive care for oncology patients (Graegis Pharmaceuticals). The company has more than a dozen active programs targeting dermatological conditions including atopic dermatitis, vitiligo, alopecia areata, chronic urticaria, psoriasis, and systemic mastocytosis.

Differentiator

Problem solved

Functional benefit

Products and services

• ALY-101 An intradermal injectable JAK1 siRNA-lipid conjugate for the treatment of Alopecia Areata. First clinical candidate from the siRNA platform developed with UMass Chan Medical School's RNA Therapeutics Institute, designed for precise target specificity, stability, enhanced skin affinity, and long-lasting clinical efficacy while minimizing systemic exposure. Received FDA Fast Track designation.
• ALY-301 A first-in-class cis-targeting bispecific antibody targeting c-Kit and CD203c, designed to selectively deplete mast cells for the treatment of Chronic Urticaria and other mast cell-driven diseases. The first mast cell-selective c-Kit inhibitor to enter the clinic, designed to enable safe chronic dosing while avoiding the safety limitations of conventional c-Kit inhibitors.

Quantifiable outcome

• ALY-101 showed durability in skin for over two months (Nature Communications publication)
• +3 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Twelve partnerships are on record, tiered core and supporting.

• UMass Chan Medical SchoolcoreStrategic or Co-development PartnerKey collaborating institution and home of co-founders John Harris (Chief Innovation Officer, Chair of Dermatology) and Craig Mello (Nobel Laureate, Blais University Chair in Molecular Medicine). Multi-year joint research with RNA Therapeutics Institute developing siRNA therapies. ALY-101 developed in collaboration with the RNA Institute of UMass Chan Medical School.
• Gustave RoussycoreStrategic or Co-development PartnerMajor European cancer research and treatment center. Co-founded by Eric Deutsch, Professor in Oncology and Radiotherapy at Université Paris-Saclay and Director of RHU LYSAIRI Project at Gustave Roussy. Collaborating on dermatology supportive care for cancer patients.
• Georgia Institute of TechnologycoreStrategic or Co-development PartnerKey collaborating institution and home of co-founder Mark Prausnitz (Regents' Professor, J. Erskine Love Professor of Chemical and Biomolecular Engineering). Partner for drug delivery technology using microneedles, lasers, ionic liquids and other microdevices.
• Empa (Swiss Federal Laboratories for Materials Science & Technology)supportingStrategic or Co-development PartnerSwiss Federal Laboratories for Materials Science & Technology. Collaborating institution for advanced materials and drug delivery research.
• Icahn School of Medicine at Mount SinaicoreStrategic or Co-development PartnerHome of co-founder Brian Kim (Vice Chair of Research, Department of Dermatology, and Director of Mark Lebwohl Center for Neuroinflammation and Sensation). Head of Alys Pharmaceuticals Scientific Advisory Board.
• Charité – Universitätsmedizin BerlinsupportingStrategic or Co-development PartnerLeading German research university hosting Phase 1/1b clinical trial of ALY-301 for Cold Urticaria. Professor Martin Metz from Charité serves as Principal Investigator for ALY-301 trial.
• Aldena TherapeuticscoreOthersOne of six subsidiaries wholly owned by Alys Pharmaceuticals following merger. Specializes in siRNA technology for dermatological applications. Developed ALY-101 siRNA-lipid conjugate platform.
• Graegis PharmaceuticalssupportingOthersOne of six subsidiaries wholly owned by Alys Pharmaceuticals. Dedicated to supporting skin and mucosa through cancer therapies and prevention of skin radiation damage in cancer patients treated with radiation therapy.
• Granular TherapeuticscoreOthersOne of six subsidiaries wholly owned by Alys Pharmaceuticals. Specializes in granulocyte-targeted therapy with mast cell-specific targeting. Developed ALY-301 mast cell-selective bispecific antibody platform.
• Klirna BiotechsupportingOthersOne of six subsidiaries wholly owned by Alys Pharmaceuticals. Revolutionizing itch treatment through intraneuronal targeting of molecular switches of itch.
• Nira BiosciencessupportingOthersOne of six subsidiaries wholly owned by Alys Pharmaceuticals. Developing photoimmunotherapy platform deployed toward immuno-dermatology with spatially defined, cell-targeted therapy using monoclonal antibody-targeted delivery.
• Vimela TherapeuticssupportingOthersOne of six subsidiaries wholly owned by Alys Pharmaceuticals. Advancing topical therapy for vitiligo with orthogonal approach to current immunomodulatory options for repigmentation.

Scale indicators4 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• AnaptysBio: Clinical-stage immunology biotech developing antibodies for inflammatory diseases including atopic dermatitis, alopecia areata, and other immuno-dermatology indications. Directly comparable pipeline focus and development stage to Alys.
• Verrica Pharmaceuticals: Specialty dermatology company developing therapeutics for skin diseases including molluscum contagiosum and common warts. Comparable as a small, focused dermatology biopharma targeting niche or underserved dermatology indications.
• Arcutis Biotherapeutics: Specialty dermatology biopharma developing best-in-class topical therapies for inflammatory skin diseases (atopic dermatitis, seborrheic dermatitis, psoriasis). Comparable to Alys as a clinical-stage dermatology pure-play with multiple approved/late-stage assets targeting immuno-dermatology indications.
• Incyte Corporation: Commercial-stage biopharma with Opzelura (ruxolitinib cream) — the first FDA-approved repigmentation therapy for vitiligo and a topical JAK inhibitor. Direct competitor to Alys's vitiligo and alopecia programs, and previously acquired Villaris Therapeutics (anti-IL-15 antibody for vitiligo) founded by Alys co-founder John Harris.
• Dermavant Sciences: Specialty dermatology company developing novel topical therapeutics (Vtama/tapinarof) for psoriasis and atopic dermatitis. Closely comparable to Alys in business model and target indications within immuno-dermatology.

Emerging players

• Almirall: European-headquartered specialty dermatology biopharma with a focused portfolio of topical and systemic dermatology treatments. Comparable as a mid-sized dermatology pure-play, particularly given Alys's European operations in Switzerland and German clinical sites.

Broad incumbents

• Sanofi: Global pharmaceutical major with Dupixent (dupilumab) co-developed with Regeneron — the dominant atopic dermatitis biologic. Sets the standard-of-care bar Alys's atopic dermatitis and chronic urticaria programs must clear, and a likely commercial partner or acquirer for late-stage assets.
• AbbVie: Major biopharma with a significant immunology and dermatology franchise including Rinvoq (upadacitinib) and Skyrizi (risankizumab), both approved in atopic dermatitis and psoriasis. Competes head-to-head with Alys in immuno-dermatology indications and could be a commercial partner.
• Pfizer: Pharmaceutical major with dermatology assets including Cibinqo (abrocitinib) and Litfulo (ritlecitinib) — JAK inhibitors directly relevant to Alys's alopecia areata (ALY-101) target. Granular Therapeutics CSO Orla Cunningham is a former Pfizer Senior Director, evidencing talent and competitive overlap.
• Galderma: Global pure-play dermatology company covering therapeutic, aesthetic, and consumer skin health. Multiple Alys executives (COO Thibaud Portal, Patrick Raboisson, Emmanuel Vial) are former Galderma R&D leaders, making it the most direct large-scale dermatology incumbent and a likely strategic acquirer or partner.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/alys-pharmaceuticals

Revenue estimate

Valuation estimate

Number of profiles

Profiles19 records

Subsidiaries6 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A6 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Alys Pharmaceuticals